Provided by Tiger Trade Technology Pte. Ltd.

Novo-Nordisk A/S

44.01
-0.5500-1.23%
Post-market: 44.050.0406+0.09%19:59 EDT
Volume:6.58M
Turnover:291.64M
Market Cap:196.50B
PE:10.99
High:44.82
Open:44.60
Low:44.01
Close:44.56
52wk High:64.16
52wk Low:35.12
Shares:4.47B
Float Shares:3.19B
Volume Ratio:0.69
T/O Rate:0.21%
Dividend:1.72
Dividend Rate:3.91%
EPS(TTM):4.00
EPS(LYR):3.62
ROE:59.82%
ROA:18.73%
PB:6.03
PE(LYR):12.16

Loading ...

Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme

TIPRANKS
·
Aug 04

Legal Inquiry Launched for Hims & Hers Health Following Share Plunge

Deep News
·
Aug 04

Novo Nordisk A/S Series B Stock Falls Monday, Underperforms Market

Dow Jones
·
Aug 04

Novo Nordisk Earnings Seen Lower; Guidance and Wegovy Pill in Focus

Dow Jones
·
Aug 03

Stock Markets Can't Rely on Tech to Power Gains Anymore

Dow Jones
·
Aug 03

Novo Nordisk A/S Expected to Post Earnings of Dkk4.99 a Share - Earnings Preview

Reuters
·
Aug 03

Earning Preview: Novo-Nordisk Q2 revenue expected to decrease by 6.01%, institutional views are neutral

Earnings Agent
·
Aug 02

Novo Nordisk (NYSE:NVO) Ziltivekimab Trial Fails In Late Stage Cardiovascular Study

Simply Wall St.
·
Aug 02

Is Novo Nordisk Stock (NVO) a Good Buy After Today’s Plunge?

TIPRANKS
·
Aug 01

Exchange Traded Funds Top 10 Percentage Losers

Dow Jones
·
Aug 01

Nasdaq Composite Index Rises 1% as Amazon Surges 15% After Results; Apple and Micron Fall as Memory Stocks Retreat

TradingKey
·
Aug 01

Monte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback

TIPRANKS
·
Aug 01

European Stocks Wipe Out Monthly Gains as Novo Nordisk and Universal Music Plunge

Deep News
·
Aug 01

Novo Nordisk A/S Stock (NVO) Moved Down by 8.75% on Jul 31: Key Drivers Unveiled

TradingKey
·
Aug 01

European Equities Mixed in Friday Trading; Novo Nordisk Says Ziltivekimab Fails to Reduce Major Adverse Cardiovascular Events in Trial

MT Newswires Live
·
Aug 01

Novo Nordisk A/S Series B Stock Falls Friday, Underperforms Market

Dow Jones
·
Aug 01

Novo Nordisk Falls Over 10% in Largest Single-Day Drop in Nearly Five Months After Announcing Heart Drug Trial Failure

TradingKey
·
Jul 31

Novo Nordisk's Stock Slumps After Failed Trial - Adding to the Company's Woes

Dow Jones
·
Jul 31

Movement Alert|Novo-Nordisk A/S Falls 8.2% in Regular Trading, Heart Drug Ziltivekimab Fails Phase 3 ZEUS Trial Primary Endpoint

Market Focus
·
Jul 31

Novo Nordisk Heart Drug Trial Failure Triggers Pre-Market Plunge, Deepening Concerns Over Weight Loss Drug Reliance

Stock News
·
Jul 31